SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-014191
Filing Date
2024-02-14
Accepted
2024-02-14 17:28:53
Documents
69
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q1223_estrella.htm   iXBRL 10-Q 707837
2 CERTIFICATION f10q1223ex31-1_estrella.htm EX-31.1 9194
3 CERTIFICATION f10q1223ex31-2_estrella.htm EX-31.2 9145
4 CERTIFICATION f10q1223ex32-1_estrella.htm EX-32.1 3455
5 CERTIFICATION f10q1223ex32-2_estrella.htm EX-32.2 3457
  Complete submission text file 0001213900-24-014191.txt   4391145

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE esla-20231231.xsd EX-101.SCH 50958
7 XBRL CALCULATION FILE esla-20231231_cal.xml EX-101.CAL 27322
8 XBRL DEFINITION FILE esla-20231231_def.xml EX-101.DEF 241392
9 XBRL LABEL FILE esla-20231231_lab.xml EX-101.LAB 424237
10 XBRL PRESENTATION FILE esla-20231231_pre.xml EX-101.PRE 250075
71 EXTRACTED XBRL INSTANCE DOCUMENT f10q1223_estrella_htm.xml XML 440492
Mailing Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608 (510) 318-9098
Estrella Immunopharma, Inc. (Filer) CIK: 0001844417 (see all company filings)

IRS No.: 861314502 | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-40608 | Film No.: 24640795
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)